This site is intended for U.S. healthcare professionals.

Deeper Than Diagnosis logo Deeper Than Diagnosis logo

Managing MDS

Assess treatment goals for your patients

Management of MDS is predominantly influenced by a patient’s risk category, which can be assessed using the IPSS-M classification.1
Risk gauge pointing to low
Risk gauge pointing to high

Goals for treatment

Reduce disease-related symptoms, lessening or eliminating transfusions, and minimizing morbidity associated with certain cytopenias2

Delay transformation to AML, prolong survival, and increase quality of life through improvement of peripheral blood counts2

Current treatment options

Supportive care agents, disease-modifying agents, clinical trials2,3

Supportive care agents, disease-modifying agents, hematopoietic stem cell transplantation (HSCT), clinical trials2

According to The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), a substantial proportion of subsets of patients with MDS lack effective treatment for their cytopenias or for altering the natural course of disease. Clinical trials with FDA-approved drugs and other novel therapeutic agents, along with supportive care, remain the hallmark of disease management.4

Treatment considerations for your patients

Hands forming a heart icon

Supportive care agents

Promote the growth and maturation of specific hematopoietic stem/progenitor cell (HSPC) lineages to address cytopenias.2

Erythropoiesis-stimulating agents (ESAs)2
Erythroid-maturation agents (EMAs) are an alternative consideration in patients who require RBC transfusion3
Granulocyte colony-stimulating factors (G-CSFs)5
Thrombopoietin-receptor agonists (TRAs)2
Red blood cell or platelet transfusions6
Chemo Icon

Disease-modifying agents

Target dysfunctional HSPCs to improve cytopenias and slow progression to AML.2,5

Hypomethylating agents (HMAs)2
Cytotoxic chemotherapy agents2
Immunosuppressive therapy (IST)5
Needle icon

Hematopoietic stem cell transplantation

HSCT is the only curative option for eligible patients with high-risk MDS.7

DNA icon

Targeted therapies

Research in therapies targeting actionable mutations is ongoing.

Targeted therapies work differently than chemotherapy as these agents work on specific types of cancer cells harboring a certain mutation and do less harm to normal cells8
Clipboard icon

Participation in clinicals trials

Clinical trials evaluating various therapies are currently ongoing in previously untreated, R/R, high-risk MDS, and low-risk MDS, aiming to fulfill the unmet clinical needs of the disease.7

Discover active clinical trials for patients with mIDH1 MDS

Assess your patient’s molecular profile at diagnosis, and retest at first suspicion of clinical change.9,10
See the latest statistics about AML
Learn more
Sign up now to receive updates about MDS and AML from Servier Pharmaceuticals.
*Indicates required field

By clicking submit, you opt in to receive email updates from Servier Pharmaceuticals. You may unsubscribe at any time. Data may be used in accordance with the Privacy Policy.

AML, acute myeloid leukemia; IPSS-M, International Prognostic Scoring System-Molecular; MDS, myelodysplastic syndromes; RBC, red blood cell; R/R, relapsed or refractory.

References: 1. Sekeres M. Patient education: myelodysplastic syndromes (mds) in adults (beyond the basics). UpToDate. Updated November 2, 2022. Accessed July 19, 2023. 2. Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328(9):872-880. doi:10.1001/jama.2022.14578 3. Kubasch AS, Platzbecker U. Setting fire to ESA and EMA resistance: new targeted treatment options in lower risk myelodysplastic syndromes. Int J Mol Sci. 2019;20(16):3853. doi:10.3390/ijms20163853 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. doi:10.1182/blood-2018-10-844696 6. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018;8(5):47. doi:https://doi.org/10.1038/s41408-018-0085-4 7. Pagliuca S, Gurnari C, Visconte V. Molecular targeted therapy in myelodysplastic syndromes: new options for tailored treatments. Cancers (Basel). 2021;13(4):784. doi:10.3390/cancers13040784 8. What is targeted therapy? Cancer.Net. Approved May 2022. Accessed July 19, 2023. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-targeted-therapy 9. Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular testing in myelodysplastic syndromes for the practicing oncologist: Will the progress fulfill the promise? Oncologist. 2015;20(9):1069-1076. doi:10.1634/theoncologist.2015-0067 10. Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182-2198. doi:10.1038/s41375-021-01265-7